CRBP
NASDAQCorbus Pharmaceuticals Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$4.50+0.24 (+5.50%)
01:30 PM07:45 PM
News · 26 weeks46-25%
2026-04-192026-10-11
Mix1990d
- Other7(37%)
- Insider6(32%)
- SEC Filings5(26%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Corbus Pharmaceuticals Holdings Inc.8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form SCHEDULE 13G filed by Corbus Pharmaceuticals Holdings Inc.SCHEDULE 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
- PRCorbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerIncidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line and beyond (2L+) oropharyngeal squamous cell carcinoma (OPSCC). "For
- INSIDERDirector Ben Yong sold $15,683 worth of shares (2,000 units at $7.84) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 9,383 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesityCRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observedCRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicinesData selected for late-breaking presentation at ObesityWeek® 2026Company will hold an investor call at 8:00am EDT today NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today
- PRCorbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In ObesityNORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic op
- INSIDERChief Medical Officer Nicacio Leonardo Viana was granted 58,333 shares (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- PRCorbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consisted of (
- INSIDERChief Business Officer Saxena Nishant C bought $25,036 worth of shares (2,600 units at $9.63), increasing direct ownership by 3% to 77,900 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Executive Officer Cohen Yuval sold $171,396 worth of shares (17,000 units at $10.08) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 157,316 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Financial Officer Moran Sean F. sold $120,971 worth of shares (12,000 units at $10.08) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 84,694 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECSEC Form 424B5 filed by Corbus Pharmaceuticals Holdings Inc.424B5 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate UpdateObtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026Appointed new Chief Medical Officer, Chief Business Officer, and Board Member to strengthen senior leadership and guide the Company through registrational studies and commercialization readiness NORWOOD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing new therapies in oncology and
- INSIDERSEC Form 3 filed by new insider Nicacio Leonardo Viana3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- PRCorbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of ObesityDose-finding Phase 1b study (n=240) on track for topline data in September 2026CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 classCRB-913 yielded 15 times lower brain penetration than monlunabant in mice NORWOOD, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical visit ("Last Patient Last Visit") in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track for topline data r
- PRCorbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal CancerCompany expects to initiate enrollment in TEMPO-1 in September 2026OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company") a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study ("TEMPO-1") of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line (2L) orophary
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical OfficerNORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. "We’re thrilled to welcome Dr. Nicacio to Corbus, particularly as we approach initiation of our TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Dr. Nicacio brings a highly relevant background in solid tumor drug development and commercialization, including his
- SECSEC Form S-8 filed by Corbus Pharmaceuticals Holdings Inc.S-8 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- INSIDERChief Business Officer Saxena Nishant C bought $101,218 worth of shares (13,500 units at $7.50), increasing direct ownership by 22% to 75,300 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECSEC Form S-8 filed by Corbus Pharmaceuticals Holdings Inc.S-8 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
CRBP FAQ
6 questionsWhat does Corbus Pharmaceuticals Holdings Inc. do?
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as...Where does CRBP stock trade?
Corbus Pharmaceuticals Holdings Inc. (CRBP) is listed on NASDAQ.What sector and industry is CRBP in?
Corbus Pharmaceuticals Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRBP?
Corbus Pharmaceuticals Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $4500.00 price target on 2026-04-29. Recent price targets range from $2800.00 to $4500.00.What companies are similar to CRBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CRBP side-by-side with any of them on Quantisnow.How can I track CRBP on Quantisnow?
Quantisnow aggregates Corbus Pharmaceuticals Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRBP to receive live email and push alerts on every new disclosure.